Back to Journals » Lung Cancer: Targets and Therapy » Volume 6

AXL receptor tyrosine kinase as a therapeutic target in NSCLC

Authors Okimoto R, Bivona T

Received 13 February 2015

Accepted for publication 25 March 2015

Published 30 April 2015 Volume 2015:6 Pages 27—34

DOI https://doi.org/10.2147/LCTT.S60438

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Prof. Dr. Pan-Chyr Yang


Ross A Okimoto,1 Trever G Bivona1,2

1Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA

Abstract: The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial–mesenchymal transition-associated drug resistance. Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models. These findings implicate AXL as a promising therapeutic target in lung cancer. In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clinical landscape of anti-AXL therapeutics.

Keywords: Gas6, lung cancer, targeted therapy, drug resistance
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]